Centromere protein L (CENPL) is involved in the mitotic process of eukaryotic cells and the development of various types of cancer. However, its role in hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate the expression and clinical significance of CENPL in HCC, and explore its involvement in regulating HCC cell proliferation, apoptosis, cell cycle, and glycolysis both in vivo and in vitro. CENPL expression was analyzed in HCC and normal liver tissues using The Cancer Genome Atlas, Gene Expression Omnibus mining, real-time quantitative polymerase chain reaction, and immunohistochemistry. Functional assays were used to assess the role of CENPL in HCC cell proliferation, apoptosis, cell cycle, and glycolysis. The potential pathways underlying the regulatory effects of CENPL, as well as the expression of mitogen-activated protein kinase (MAPK) signaling pathway-related molecules and markers of proliferation and glycolysis were investigated. CENPL was significantly upregulated in HCC tissue and associated with multiple clinicopathological features and poor patient prognosis. Univariate and multivariate analyses demonstrated that CENPL may serve as an independent prognostic factor for HCC. Upregulation of CENPL in HCC regulated tumor proliferation and glycolytic processes. Mechanistic studies revealed that differentially expressed genes between the CENPL-overexpressing and control groups were mainly concentrated in the MAPK signaling pathway. Pathway inhibition analysis indicated that CENPL activated the MEK1/2-ERK1/2 signaling pathway to promote proliferation and glycolysis in HCC cells. This study elucidated the role of CENPL in regulating cell proliferation, apoptosis, cell cycle, and glycolysis in HCC. CENPL may represent a therapeutic target and prognostic biomarker for HCC.
25 September 2022 in International Journal of General Medicine
Purpose: To examine the expression, clinical significance, and potential regulatory mechanism of centromere protein O (CENPO) in hepatocellular carcinoma (HCC). Methods: CENPO expression in pan-cancer was studied using the TCGA-GTEx database, in HCC and normal liver tissues using the GEO and TCGA databases, and in clinical HCC samples by RT-qPCR. The diagnostic value of CENPO was assessed using receiver operating characteristic curves. Univariate and multivariate regression analyses of factors associated with HCC prognosis were performed. CENPO function and its mechanism in HCC were explored using GO, KEGG, and GSEA analyses of differentially expressed genes (DEGs). Association of CENPO expression with immune cell infiltration and immune checkpoint-associated molecules was conducted using TCGA data and the TIMER2.0 database. Relationships between CENPO expression and DNA methylation were analyzed using the UALCAN and cBioPortal databases. CENPO expression in HCC cell lines was detected using RT-qPCR. Results:CENPO is upregulated in most cancers, including HCC and cell lines, and is a potential biomarker for HCC diagnosis (AUC = 0.936, 95% CI: 0.911– 0.960). Higher CENPO expression was associated with poorer outcomes in patients with HCC (OS, p = 0.004; DSS, p = 0.002; PFI, p < 0.001), and CENPO was an independent predictor of factors influencing overall survival in HCC. DEGs between samples with high and low CENPO levels were enriched in various biological processes, including activation of the G2M checkpoint and other signaling pathways, while CENPO expression correlated with HCC immune cell infiltration and immune checkpoint-associated molecules, as well as CENPO promoter methylation (p < 0.001). Conclusion: In HCC and cell lines, CENPO is overexpressed, a potential diagnostic marker and an indicator of poor prognosis. CENPO may regulate HCC development by influencing nuclear division and tumor immune infiltration and is regulated by methylation, making it a potential target for HCC immunotherapy.
Rationale: Cystic duct (CD) variations are common biliary tract alterations; therefore, caution is required in the diagnosis and treatment of cholelithiasis in patients with gallbladder duct anomalies. Laparoscopic cholecystectomy (LC) is the preferred method for treating cholelithiasis or cholecystitis. Accurate preoperative imaging assessment, a thorough understanding of relevant surgical anatomy, and intraoperative precautions are required to effectively reduce the incidence of intraoperative bile duct injury. Patient concerns: We report the case of a 59-year-old male patient with common hepatic duct (CHD) stricture following LC. The patient’s CD entered the common bile duct from the left side and ran ventrally around the common bile duct. Postoperative examination revealed partial stenosis of the CHD caused by compression from an absorbable ligation clip and transient hyperbilirubinemia. Fortunately, prompt treatment prevented serious complications. Diagnoses: Cholelithiasis with cholecystitis and CD anatomical variation. Interventions: LC. Outcomes: Postoperative examination revealed partial stenosis of the CHD caused by compression from an absorbable ligation clip, with transient hyperbilirubinemia. The patient was discharged 3 days postoperatively and followed up for 10 months. The absorbable ligation clips were resorbed, and the CHD stenosis resolved. Lessons: Biliary tract surgeons must understand and master common variations of the CD and their clinical significance. Potential anatomical variations should be identified preoperatively, while the extrahepatic bile ducts should be carefully exposed intraoperatively. Whenever possible, absorbable ligation clips should be used to transect the CD while avoiding compression of the bile duct to prevent bile duct injury.